Abcam, ab257738, Human TFG (TRK fused gene) knockout HeLa cell lysate

Size: 1Kit
TFG KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon2 and Insertion of the selection cassette in exon2.
Key facts
Cell type:HeLa,
Species or organism:Human,
Tissue:Cervix,
Knockout validation:Sanger Sequencing,Western blot,
Mutation description:Knockout achieved by using CRISPR/Cas9, 19 bp deletion in exon2 and Insertion of the selection cassette in exon2.,
Disease:Adenocarcinoma

Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-TFG, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Western blot, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The TRK fused gene also known as NTRK or tropomyosin receptor kinase encodes for a family of proteins integral to neurotrophin signaling. These proteins weighing approximately 80-90 kilodaltons include isoforms such as TRKA TRKB and TRKC which are products of the NTRK1 NTRK2 and NTRK3 genes respectively. They express mainly in neuronal tissues and certain non-neuronal cells. These proteins possess a diverse range of functions largely due to structural variations derived from gene fusions.
Biological function summary
Neurotrophin signaling pathways involve TRK proteins facilitating neuronal differentiation survival and plasticity. TRK proteins often form part of larger complexes engaged in transmitting signals from the extracellular environment to intracellular pathways. The TRK proteins interact with neurotrophins like NGF BDNF and NT-3 playing essential roles in nervous system function and development. The interaction between TRK receptors and their ligands activates downstream signaling cascades.
Pathways
TRK proteins significantly contribute to the MAPK/ERK and PI3K/Akt pathways. These pathways control cell growth differentiation and survival. Within these pathways TRK proteins interact with partners such as Ras and Akt coordinating a broad range of cellular processes. They ensure proper cellular responses to external stimuli and maintain homeostasis within the cell.
TRK fusion proteins frequently associate with certain cancers including thyroid and lung cancer due to gene fusions leading to overactive signaling. Altered TRK signaling correlates with neurodegenerative diseases as well such as Alzheimer's disease. TRK fusions can affect proteins like ETV6 and LMNA in the context of cancer influencing tumorigenesis and disease progression. Understanding the connections between TRK fusions and these diseases aids the development of target-specific therapies.